Nano-Drug Delivery Systems Targeting CAFs: A Promising Treatment for Pancreatic Cancer
DOI: https://doi.org/10.2147/ijn.s451151
IF: 7.033
2024-03-18
International Journal of Nanomedicine
Abstract:Mingjie Wang, 1, &ast Wenxiang Xue, 2, &ast Hanghang Yuan, 2 Zhicheng Wang, 2 Lei Yu 1 1 Department of Radiotherapy, Second Hospital of Jilin University, Changchun, Jilin, People's Republic of China; 2 NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, Jilin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhicheng Wang; Lei Yu, Tel +86-431-85619443, Email ; Currently, pancreatic cancer (PC) is one of the most lethal malignant tumors. PC is typically diagnosed at a late stage, exhibits a poor response to conventional treatment, and has a bleak prognosis. Unfortunately, PC's survival rate has not significantly improved since the 1960s. Cancer-associated fibroblasts (CAFs) are a key component of the pancreatic tumor microenvironment (TME). They play a vital role in maintaining the extracellular matrix and facilitating the intricate communication between cancer cells and infiltrated immune cells. Exploring therapeutic approaches targeting CAFs may reverse the current landscape of PC therapy. In recent years, nano-drug delivery systems have evolved rapidly and have been able to accurately target and precisely release drugs with little or no toxicity to the whole body. In this review, we will comprehensively discuss the origin, heterogeneity, potential targets, and recent advances in the nano-drug delivery system of CAFs in PC. We will also propose a novel integrated treatment regimen that utilizes a nano-drug delivery system to target CAFs in PC, combined with radiotherapy and immunotherapy. Additionally, we will address the challenges that this regimen currently faces. Keywords: nanoparticle, nano-drug delivery system, cancer-associated fibroblasts, pancreatic cancer, tumor microenvironment Pancreatic cancer (PC) is a highly aggressive disease that has been causing a gradual increase in morbidity and mortality. In recent decades, only about 4% of patients have been able to survive 5 years after diagnosis. The survival rate of PC has stagnated due to its resistance to current conventional therapies, including surgery, chemotherapy, radiotherapy, and immunotherapy. Additionally, the fact that most patients are detected at an advanced stage contributes to the challenge. 1 The resistance of PC to current therapeutic modalities is primarily attributed to the structural characteristics of PC itself, as it is surrounded by a rich tumor microenvironment (TME). The rich TME not only produces various pro-tumor growth and metastatic active factors, but also serves as a physical barrier preventing drug penetration from reaching the tumor. 2 Cancer-associated fibroblasts (CAFs) play a crucial role in the composition of the TME, which is a major component in the composition and regulation of the tumor's physical barrier. CAFs can be differentiated from normal fibroblasts and PC astrocytes and they can be classified into numerous subtypes. 3 Different subtypes of CAFs secrete a variety of regulatory factors that play crucial roles in PC proliferation, invasion, and metastasis. However, recent studies have shown that excessive depletion of CAFs accelerates tumor progression. 4 CAFs, with their pro-tumorigenic and anti-tumorigenic functional heterogeneity, are promising targets for the treatment of PC. Currently, there are no effective therapeutic modality available to improve the prognosis of PC. Novel regimens targeting the CAFs that comprise the TME may revolutionize the current landscape of PC treatment. The ability to remodel the TME to reverse the physical barrier that protects tumor cells and creates a rapid pathway for drug penetration is crucial. Currently, there is no effective treatment to improve the prognosis of PC. However, there has been limited progress in efficiently targeting CAFs and appropriately converting tumor-promoting CAFs into anti-tumor CAFs. The use of nano-drug delivery systems has made significant advancements in recent years. These systems not only enable precise targeting of the affected area but also allow for precise temporal, spatial, and dosimetric release of drugs through suitable stimulus-responsive systems. 5 Nanosystems can also target specific organelles and signaling pathways after entering cells to interfere with energy metabolism and signaling in tumor cells. This interference affects the function of tumor cells and has the potential to target CAFs in the treatment of PC. 6 Furthermore, these nanosystems are virtually non-toxic to normal tissues, making them highly promising for targeted therapy. Dual targeting of CAFs and their internal organelles by nanosystems may help alleviate the issue of accelerated tumor progression -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology